MoroccoTuberculosis profile
Population  2016 35 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.3 (2.1–4.7) 9.3 (6–13)
Mortality (HIV+TB only) 0.074 (0.035–0.13) 0.21 (0.1–0.36)
Incidence  (includes HIV+TB) 36 (31–42) 103 (88–119)
Incidence (HIV+TB only) 0.44 (0.29–0.63) 1.3 (0.81–1.8)
Incidence (MDR/RR-TB)** 0.64 (0.38–0.9) 1.8 (1.1–2.5)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 2 (1.7–2.3) 13 (11–14) 15 (12–17)
Males 2.3 (1.9–2.6) 19 (17–22) 22 (18–25)
Total 4.3 (3.6–4.9) 32 (27–37) 36 (31–42)
TB case notifications, 2016  
Total cases notified 32 246
Total new and relapse 31 542
          - % tested with rapid diagnostics at time of diagnosis 1%
          - % with known HIV status 47%
          - % pulmonary 54%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.09 (0.06–0.13)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 208 1%
          - on antiretroviral therapy 172 83%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  380
(270–500)
Estimated % of TB cases with MDR/RR-TB 1% (0.3–1.7) 11% (9.5–12)  
% notified tested for rifampicin resistance 5% 71% 3 158
MDR/RR-TB cases tested for resistance to second-line drugs   223
Laboratory-confirmed cases MDR/RR-TB: 236, XDR-TB: 13
Patients started on treatment **** MDR/RR-TB: 238, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 88% 30 636
Previously treated cases, excluding relapse, registered in 2015 72% 767
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 60% 124
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 27%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
1.1% (1–1.2)
TB financing, 2017  
National TB budget (US$ millions) 16
Funding source: 82% domestic, 13% international, 5% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data